Overview


According to FutureWise analysis the market for advanced parenteral drug delivery devices is expected to register a CAGR of 9.22% from 2023-2031.

The advanced parenteral drug delivery system represents a groundbreaking evolution in pharmaceutical science, offering a sophisticated and refined approach to the administration of therapeutic agents directly into the body. This intricate method encompasses various cutting-edge techniques, including injections and infusions, aiming to transport pharmaceutical substances efficiently into the bloodstream while circumventing the complexities of the digestive system. In contrast to conventional parenteral methods that often involve straightforward injections, these advanced systems comprise a diverse array of state-of-the-art technologies, devices, and strategies, collectively aimed at enhancing the precision of drug administration, elevating patient comfort, and optimizing overall treatment efficacy. These advanced systems hold particular significance for medications characterized by challenges such as a narrow therapeutic index, where slight variations in dosage can have significant impacts, or limited bioavailability, where only a fraction of the drug reaches systemic circulation. Additionally, these systems are advantageous in cases where patients are unable to ingest medications orally, such as unconscious patients or those experiencing difficulty in swallowing. 

The spectrum of advanced parenteral approaches encompasses various innovative modalities such as Smart devices integrate electronic components for drug delivery, automated dosing, monitoring, and healthcare provider communication. Wearable injectors offer continuous dosing with mobility, vital for chronic conditions. Implantable devices gradually release medication, especially valuable for sustained therapy. Microneedles enable painless transdermal drug delivery, ideal for self-administration. Liposomal and nanoparticle formulations target and control drug release, minimizing side effects. Intravenous infusion systems allow controlled administration, crucial in emergencies. Personalized drug delivery, driven by advanced tech, tailors dosages for optimal outcomes, embodying patient-centered care.

FutureWise Market Research has published a report that provides an insightful analysis of Advanced Parenteral Drug Delivery Devices Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Advanced Parenteral Drug Delivery Devices Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • AptarGroup Incorporated
  • Amgen Incorporated
  • Abbott Laboratories
  • Baxter International Incorporated
  • Becton, Dickinson and Company
  • Bristol-Myers Squibb Company
  • Boston Scientific Corporation
  • GlaxoSmithKline plc
  • Roche Holding Limited
  • Novartis AG
  • Pfizer
  • AstraZeneca plc

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Development in Advanced Parenteral Drug Delivery Devices Market:

  • In February 2022, Takeda obtained endorsement by the United States Food and Drug Administration (FDA) for the utilization of TAKHZYRO (lanadelumab-flyo) injection through a single-dose prefilled syringe (PFS). This application aims to prevent hereditary angioedema (HAE) attacks in adult and pediatric patients aged 12 years and above.
  • In January 2022, Diazepam Injection, USP, was introduced to the market by Hikma Pharmaceuticals USA Inc., a subsidiary of Hikma Pharmaceuticals. This newly launched product is available in a 5mg/mL dosage, enclosed within a 2mL prefilled syringe. With the introduction of this product, Hikma Pharmaceuticals has successfully introduced its second medication in the prefilled syringe format.

The market's growth is propelled by several compelling drivers, including the escalating prevalence of chronic diseases like diabetes and cardiovascular ailments that demand precise drug delivery. The advent of pioneering drug formulations such as biologics and personalized medicines further underscores the need for advanced parenteral devices to maintain formulation stability and enhance drug absorption. The aging global population adds to this momentum, requiring user-friendly drug delivery options. At the same time, technological advancements like smart devices and wearable injectors provide novel ways of administering medications and monitoring treatments. Additionally, the shift towards patient-centric care amplifies the demand for convenient drug administration solutions, propelling the adoption of these devices.

However, the market has its challenges. Stringent regulatory frameworks pose hurdles for device manufacturers, demanding adherence to rigorous safety and efficacy standards. Developing these sophisticated devices incurs high costs due to specialized materials, intricate manufacturing processes, and stringent quality control measures. Concerns about device malfunctions and errors necessitate a strong focus on reliability and safety. Moreover, patients and healthcare providers unfamiliar with these novel devices require substantial educational efforts. The shift towards self-administration, while convenient, raises concerns about proper training, storage, disposal, and potential misuse. Adoption barriers may arise in regions with inadequate healthcare infrastructure due to a need for more trained personnel and facilities.

By Product Type

  • Prefillable Syringes
  • Injectors Cartridges
  • Hypodermic Syringes
  • IV Catheters
  • Others

By Application

  • Central Nervous System Agents
  • Respiratory Agents
  • Hormones and Related Agents
  • Gastrointestinal Agents
  • Cardiovascular Agents
  • Anti-infective Agents
  • Nutritional Agents
  • Genito-urinary Agents

By End-User

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America accounts for the largest share globally in this market due to increased adoption of advanced technologies in drug delivery devices, improved drug delivery solutions, and expanded healthcare infrastructure with vital healthcare expenditure drives the market in this region. In addition, the surge in patient awareness levels and the growing incidence of chronic illness are the major drivers fueling the expansion of this region's parenteral drug delivery devices market. Moreover, government initiatives and funds raised for more research and development drive the market.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Advanced Parenteral Drug Delivery Devices Market By Product Type, By Application, By End-User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- Product Type launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Advanced Parenteral Drug Delivery Devices Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Advanced Parenteral Drug Delivery Devices Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Advanced Parenteral Drug Delivery Devices Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Advanced Parenteral Drug Delivery Devices Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Prefillable Syringes
        2. Injectors Cartridges
        3. Hypodermic Syringes
        4. IV Catheters
        5. Others

  • 8.   Global Advanced Parenteral Drug Delivery Devices Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Central Nervous System Agents
        2. Respiratory Agents
        3. Hormones and Related Agents
        4. Gastrointestinal Agents
        5. Cardiovascular Agents
        6. Anti-infective Agents
        7. Nutritional Agents
        8. Genito-urinary Agents

  • 9.   Global Advanced Parenteral Drug Delivery Devices Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinics
        3. Diagnostic Centers
        4. Ambulatory Surgical Centers
        5. Others

  • 10.   North America Advanced Parenteral Drug Delivery Devices Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Advanced Parenteral Drug Delivery Devices Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Advanced Parenteral Drug Delivery Devices Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.  Asia Pacific Advanced Parenteral Drug Delivery Devices Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •         1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.  Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •         1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.  Market Share Analysis and Competitive Landscape
    •        1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Types Offered and Financial Layouts)
    •        1. AptarGroup Incorporated
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Amgen Incorporated
         2.1. Company Overview
         .2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Abbott Laboratories
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Baxter International Incorporated
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Becton, Dickinson and Company
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Bristol-Myers Squibb Company
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Boston Scientific Corporation
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8.GlaxoSmithKline plc
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Roche Holding Limited
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Novartis AG
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11.Pfizer
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12.AstraZeneca plc
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview

  • 17.  Pre and Post COVID-19 Impact
    •          1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients